RongliflozinAlternative Names: HEC44616
Latest Information Update: 26 Aug 2016
At a glance
- Originator HEC Pharm
- Class Antihyperglycaemics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 05 Nov 2015 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route) (HEC Pharm pipeline, November 2015)